TBPH Theravance Biopharma Inc

USD 9.01 0.19 2.154195
Icon

Theravance Biopharma Inc (TBPH) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 9.01

+0.19 (+2.15)%

USD 0.43B

0.32M

USD 10.00(+10.99%)

USD 0.00 (-100.00%)

Icon

TBPH

Theravance Biopharma Inc (USD)
COMMON STOCK | NSD
USD 9.01
0.00 0
Take a Tour
stockTargetAdvisor

Hold

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.43B

USD 0.00 (-100.00%)

USD 9.01

Theravance Biopharma Inc (TBPH) Stock Forecast

USD 10.00
(+10.99%)

Based on the Theravance Biopharma Inc stock forecast from 1 analysts, the average analyst target price for Theravance Biopharma Inc is USD 10.00 over the next 12 months. Theravance Biopharma Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Theravance Biopharma Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Theravance Biopharma Inc’s stock price was USD 9.01. Theravance Biopharma Inc’s stock price has changed by +0.00% over the past week, -7.02% over the past month and -16.50% over the last year.

No recent analyst target price found for Theravance Biopharma Inc
No recent average analyst rating found for Theravance Biopharma Inc

Company Overview Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary ...Read More

https://www.theravance.com

901 Gateway Boulevard, South San Francisco, CA, United States, 94080

99

December

USD

USA

Adjusted Closing Price for Theravance Biopharma Inc (TBPH)

Loading...

Unadjusted Closing Price for Theravance Biopharma Inc (TBPH)

Loading...

Share Trading Volume for Theravance Biopharma Inc Shares

Loading...

Compare Performance of Theravance Biopharma Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for TBPH

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Theravance Biopharma Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S -1.36 (-1.05%) USD554.45B 46.01 4.80

ETFs Containing TBPH

Symbol Name TBPH's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Theravance Biopharma Inc (TBPH) Stock

Based on ratings from 1 analysts Theravance Biopharma Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Bearish. The stock has buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on TBPH's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for TBPH is USD 10.00 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 10.

Unfortunately we do not have enough data on TBPH's stock to indicate if its overvalued.

The last closing price of TBPH's stock was USD 9.01.

The most recent market capitalization for TBPH is USD 0.43B.

Based on targets from 1 analysts, the average taret price for TBPH is projected at USD 10.00 over the next 12 months. This means that TBPH's stock price may go up by +10.99% over the next 12 months.

We can't find any ETFs which contains Theravance Biopharma Inc's stock.

As per our most recent records Theravance Biopharma Inc has 99 Employees.

Theravance Biopharma Inc's registered address is 901 Gateway Boulevard, South San Francisco, CA, United States, 94080. You can get more information about it from Theravance Biopharma Inc's website at https://www.theravance.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...